2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Emerging Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Biological Processes, Pathogenesis, Immune Mechanism, Microbiome, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Immunology, Autoimmune Disorders, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, ALL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, AML, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

5943 Bicistronic CD19/CD22 CAR T-cells achieve complete remissions and modifiable toxicities in children, adolescents, and young adults with B-cell acute lymphoblastic leukemia (ALL): Updated results from a phase I trial

Alexandra Dreyzin, MD, MS, Sara K Silbert, MD2, Josquin Moraly, MD3, Joseph Rocco, MD4, Lipei Shao, PhD5, Brynn Duncan, MD6, Alexander W Rankin, MD7, Bonnie Yates, MSN8, Grace Li, NP9, Flavia Mesquita Gava, MD10, Hannah Song, PhD11, Zhijie Wu, PhD12, Toni Foley13, Casey McGrath14, John A. Ligon15, Haneen Shalabi, DO16, Hao-Wei Wang, MD, PhD17, Constance Yuan, MD, PhD18, Dana Delgado Colon, MD19, Kathryn Martin20, Pamela Garces21, Nan Zhang, PhD22, Anh Dinh, MD23, Christopher Daniel Chien, PhD24, Steven L Highfill, PhD25, Ping Jin26, Gregoire Altan-Bonnet27, David F Stroncek, MD28, Naomi Taylor, MD, PhD29, Nirali N. Shah, MD, MHSc30
1 National Institutes of Health, Bethesda, Maryland, United States, National Institutes of Health, Bethesda, Maryland, United States
2 National Institutes of Health, Bethesda, Maryland, United States
3 National Institutes of Health, Bethesda, Maryland, United States
4 National Institutes of Health, Bethesda, Maryland, United States
5 National Institutes of Health, Bethesda, Maryland, United States
6 Kite Pharma, Frederick, Maryland, United States
7 National Institutes of Health, Bethesda, Maryland, United States, Nationwide Children's Hospital, Columbus, Ohio, United States
8 National Institutes of Health, Bethesda, Maryland, United States, University of Colorado Denver Children's Hospital, Denver, Colorado, United States
9 National Institutes of Health, Bethesda, Maryland, United States
10 National Institutes of Health, Bethesda, Maryland, United States
11 National Institutes of Health, Bethesda, Maryland, United States
12 National Institutes of Health, Bethesda, Maryland, United States
13 National Institutes of Health, Bethesda, Maryland, United States
14 National Institutes of Health, Bethesda, Maryland, United States
15 National Institutes of Health, Bethesda, Maryland, United States, University of Florida, Gainesville, Florida, United States
16 National Institutes of Health, Bethesda, Maryland, United States
17 National Institutes of Health, Bethesda, Maryland, United States
18 National Institutes of Health, Bethesda, Maryland, United States
19 National Institutes of Health, Bethesda, Maryland, United States
20 National Institutes of Health, Bethesda, Maryland, United States
21 National Institutes of Health, Bethesda, Maryland, United States
22 National Institutes of Health, Bethesda, Maryland, United States
23 National Institutes of Health, Bethesda, Maryland, United States
24 National Institutes of Health, Bethesda, Maryland, United States
25 National Institutes of Health, Bethesda, Maryland, United States
26 National Institutes of Health, Bethesda, Maryland, United States
27 National Institutes of Health, Bethesda, Maryland, United States
28 National Institutes of Health, Bethesda, Maryland, United States
29 National Institutes of Health, Bethesda, Maryland, United States
30 National Institutes of Health, Bethesda, Maryland, United States

Introduction: Our initial experience with bicistronic CD19.28z/CD22BBz CAR T-cells in relapsed/refractory (r/r) B-ALL demonstrated 1) dose-dependent toxicities and 2) a high complete remission rate, with 6/6 patients achieving measurable residual disease (MRD) negative complete remission (CR). With additional patients infused, we report updated clinical results and correlative studies informing dual-antigen targeting. (NCT05442515)

Methods: Patients aged 3-39 years with r/r B-ALL were enrolled. Autologous CD19/CD22 CAR T-cells were manufactured on the CliniMACS Prodigy following CD4/CD8-T-cell selection. Following lymphodepletion, CAR T-cells were infused at 1x106 CAR T-cells/kg [dose level 1(DL1)] or 3x105 CAR T-cells/kg (DL-1). Patients at DL-1 were stratified by disease burden [high-disease: bone marrow (BM) blasts >25% or non-CNS extramedullary disease (EMD)]. Toxicity mitigation included tocilizumab for >24 hours of fever, corticosteroids for ongoing fever, and early initiation of emapalumab and/or siltuximab for persistent symptoms.

Correlative studies included CAR T-cell differentiation and exhaustion profiling, expansion and persistence, in vivo cytokine assessments using Olink proteomics, single-cell sequencing, and in vitro cytokine production studies.

Results: Eleven patients [91% male, median age 24 yrs (range 11-29 yrs)] received bicistronic CD19.28z/CD22BBz CAR T-cells. After severe toxicities occurred in 3 of 4 patients at DL1[Gr > 3 CRS (n=3) and dose-limiting toxicities of Gr ≥ 3 immune effector cell-associated neurotoxicity syndrome (ICANS) (n=2)], dose de-escalation to DL-1 and stratification by disease burden resulted in no ICANS or severe toxicities in all 7 patients treated at DL-1. Collectively, all 11 achieved MRD negative CR, including EMD eradication in 7 of 7 patients. Seven of 11 (64%) proceeded to consolidative stem cell transplant. Among those who did not go on to transplant (n=4), 2 remain in remission without interval therapy >36 months post-infusion. With median follow up of 15 months (range 3-37 mo), overall survival was 73% and 64% at 6 and 12 months, respectively. Relapse free survival was 64% and 36% at 6 and 12 months, respectively. No deaths were attributable to CAR therapy.

The key factor associated with ICANS was high BM disease burden [93% and 94% vs median 4.4% (range 0-70%) among those without ICANS]. Neither ICANS patient had baseline EMD or CNS disease. While peak expansion, T-cell differentiation, and exhaustion profiles were similar between those with and without ICANS, % CAR in BM at Day 28 was higher [25.7% and 69%, versus median 4.0% (range 0-78%)] and peripheral blood CAR persistence was longer [118 and 167 days vs median 34 days (range 20-79 days)] in ICANS patients. Those with ICANS also had higher peak elevations of IL-2, IL-6, IL-8, TNFα, and IFNγ.

Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) (all grade 2) was seen in 4 patients (1 at DL1, 3 at DL-1), suggesting enhanced CD22 targeting compared with our prior bivalent construct, in which no IEC-HS was observed. Those with IEC-HS also had higher BM disease burden and %CAR in BM at Day 28 (66% BM blasts vs 4% in those without IEC-HS; 19% CAR on Day 28 vs 2% in those without IEC-HS). Their cytokine profiles showed higher expression of IFNγ, IL-10, ADA, IL-2, and CCL4 at Day +7, aligning with IEC-HS onset. Emapalumab was used in 5 patients (2 for CRS; 3 for IEC-HS) and resulted in a notable decrease in cytokines and Type II interferon immune activation pathways in peripheral blood mononuclear cells.

Despite higher in vivo inflammatory responses in patients with ICANS, their infusion products in vitro exhibited quantitatively distinct, but not elevated, cytokine signatures following co-culture with CD19+ and/or CD22+ leukemic cells. Consistent with effective dual-antigen targeting, robust cytokine responses were observed against either single-antigen target and further increased against CD19?CD22? cells. 

Conclusions: Bicistronic 19/22 CAR T-cells induced MRD-negative CRs in all treated patients with r/r B-ALL, including those with EMD. Severe ICANS, observed at DL1 in high-disease burden patients, was mitigated by dose reduction and early use of anti-inflammatory medications, including emapalumab. Demonstration of robust cytokine production against CD19+/CD22- and CD19-/CD22+ leukemia has supported expansion of the trial to patients with CD19-negative or CD22-negative disease.

Alexandra Dreyzin, MD, MS: No relevant conflicts of interest to declare.